Jerrydylan, Neuro could best address the SSRI patent question, but as for how the AMPA upmodulation IP came to rest in Cortex's hands, I think it was largely because no one else believed AMPA upmodulation could work without creating horrendous excitotoxicity/seizures. By the time other companies finally got interested, Cortex had already locked up all the key use patents. It's unusual for one company to have such a strong IP hold on a new pharma platform.
Ironically, the last time Cortex got into a real funk (the post-Shire debacle / sub-dollar period), it was positive news on the patent challenge front that helped save the day (along with hiring Dr. Stoll and getting some financing).
News 
Market Data 
Discover 
AI
